Asx Par News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Rating) insider Helen Fisher bought 10,204 shares of the stock in a transaction dated Thursday, May 18th. The shares were acquired at an average cost of A$0.98 ($0.65) per share, for a total transaction of A$10,020.33 ($6,680.22). Paradigm Biopharmaceuticals Price Performance The company has a debt-to-equity ratio of 0.53, […]

Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Rating) insider Paul Rennie bought 73,851 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were purchased at an average price of A$1.03 ($0.69) per share, with a total value of A$75,992.68 ($51,001.80). Paradigm Biopharmaceuticals Stock Performance The company has a quick ratio […]

“The achievements of FY21 are important in our journey as a company and help set a strong foundation for Paradigm to grow,” says interim chair and CEO.

Paradigm Biopharmaceuticals receives US FDA feedback on IND application for PPS in knee OA The company is on track to respond to questions from the US Food and Drug Administration around its Investigational New Drug application within 30 days. Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia. Paradigm Biopharmaceuticals Ltd (ASX:PAR) (OTCMKTS:PBIGF) has received written feedback from the US Food and Drug Administration (FDA) regarding the investigational new drug (IND) submission for its pivotal study evaluating Pentosan Polysulfate Sodiu...

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactive's Andrew Scott they've received first revenue through...